Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis
- Results could determine bosakitug’s development path and competitive positioning in atopic dermatitis
- Phase 2b ALPHA trial initiated for oral modzatinib in moderate-to-severe lichen planus
- Randomized, double-blind, placebo-controlled design supports higher-quality efficacy and safety assessment
- Two clinical updates advance Aclaris’s pipeline across atopic dermatitis and lichen planus
Item 8.01 · Other Events
- Bosakitug Phase 2 missed its Week 24 primary endpoint and secondary endpoints, materially weakening its eczema development outlook
- Robust TSLP target engagement and immune biomarker downregulation did not translate into clinical efficacy
- Bosakitug generally well tolerated, preserving safety support despite efficacy failure
- ALPHA Trial oral erosive lichen planus results expected in the second half of 2027, extending a key clinical catalyst timeline
- ATI-9494 IND filing targeted for Q4 2026, with Phase 1 SAD/MAD dosing and proof-of-concept plans supporting pipeline advancement
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 ADMIRATION trial failed primary and secondary endpoints in moderate-to-severe atopic dermatitis
- Bosakitug showed robust TSLP target engagement but no demonstrated clinical efficacy, weakening its standalone AD opportunity
- Bosakitug was generally well tolerated, but development priorities remain oral kinase inhibitors and ATI-052
- Phase 2b modzatinib trial initiated in lichen planus; ATI-9494 IND filing expected this quarter
- ATI-052 Phase 2b trial in eosinophilic esophagitis planned for Q1 2027
Item EX-99.2 · Exhibit EX-99.2
- Phase 2b A LP HA trial initiated for modzatinib in moderate-to-severe lichen planus, expanding the lead asset into a disease with no FDA-approved targeted therapies
- Approximately 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts, with two dose levels versus placebo
- Primary endpoints assessed at Week 16 for oral and cutaneous disease, and Week 24 for lichen planopilaris
- Topline oral erosive lichen planus results expected in the second half of 2027, establishing the next major clinical catalyst
- FDA Fast Track designation may support development, but efficacy and safety remain unvalidated in this Phase 2b indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.